The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 333:942-943 October 5, 1995 Number 14
NextNext

Cytokine Therapy in Septic Shock

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Chrousos, G. P.
-PubMed Citation
To the Editor: The review of interactions between the immune system and the hypothalamic–pituitary–adrenal axis by Chrousos (May 18 issue)1 contains controversial comments on therapeutic options in sepsis. The suggestion to use {beta}2-agonists and {alpha}2-noradrenergic antagonists to stimulate the secretion of interleukin-6 overlooks the effect of these agents on the circulation. In particular, the administration of such drugs would be likely to compound the decreased systemic vascular resistance and hypotension that are characteristic of septic shock. The notion that interleukin-6 might prove useful in septicemia can itself be contested. The results that suggest a beneficial effect of interleukin-6 treatment in . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.